

H.F. 3026

As amended by H3026DE1-2

Subject MA Coverage and Clinical Trials

Authors Mann and others

Analyst Randall Chun

Date March 2, 2020

Summary

Section Description

1 Investigational drugs, biological products, and devices.

Amends § 256B.0625, subd. 64. Clarifies that MA and the early periodic screening, diagnosis, and treatment (EPSDT) program do not cover the cost of treatment that is part of an approved clinical trial, as defined in section 62Q.526. States that participation of an enrollee in an approved clinical trial does not preclude MA coverage of medically necessary covered services that are not related to the approved clinical trial.